According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

The move targets thimerosal, a preservative that anti-vaccine activists blame for neurodevelopmental disorders, despite ...

Health and Human Services Secretary Robert F. Kennedy Jr. ordered that thimerosal, a mercury-based preservative, be removed from US flu shots based on a recommendation from an influential vaccine ...

The new guidance on vaccines, such as those that protect against COVID-19, influenza, and RSV, will be released by the end of the summer, ahead of respiratory season.

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory ...

Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...